Our previous study found that tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) expressing umbilical vein endothelial cell membrane‐based nanoplatforms can be applied for targeted anti‐arthritis therapy by binding and neutralizing multiple complex pathological factors vesicles.[23] However, the pathogenesis of RA is complex, in which a variety of cells are involved, and the selection of the appropriate cell membrane for encapsulation to achieve high specificity and broad‐spectrum anti‐inflammatory effects still needs to be studied. The gene discussed is TNFSF10; the disease is rheumatoid arthritis.